Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
IPSS-R
MDS
Micromegakaryocytes
myelodysplastic syndromes
myeloid dysplasia
prognostic factor
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
pubmed:
1
1
2022
medline:
26
5
2022
entrez:
31
12
2021
Statut:
ppublish
Résumé
Micromegakaryocytes (microMKs) are considered a myelodysplastic feature of myeloid neoplasms in adults, with an adverse prognosis connotation. However, this notion in MDS has not been well proved. In our cohort of 287 MDS, patients with microMKs showed lower overall survival (OS) (HR, 2.12; 95% CI, 1.47-3.06;
Identifiants
pubmed: 34969346
doi: 10.1080/10428194.2021.2018581
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM